From formulation to structure: 3D electron diffraction for the structure solution of a new indomethacin polymorph from an amorphous solid dispersion
Source abstract
Abstract
3D electron diffraction (3DED) is increasingly employed to determine molecular and crystal structures from micro-crystals. Indomethacin is a well known, marketed, small-molecule non-steroidal anti-inflammatory drug with eight known polymorphic forms, of which four structures have been elucidated to date. Using 3DED, we determined the structure of a new ninth polymorph, σ, found within an amorphous solid dispersion, a product formulation sometimes used for active pharmaceutical ingredients with poor aqueous solubility. Subsequently, we found that σ indomethacin can be produced from direct solvent evaporation using dichloromethane. These results demonstrate the relevance of 3DED within drug development to directly probe product formulations.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems · Crystallography and molecular interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Andrusenko · Int. J. Pharm. · 2021 · 608 · 12106710.1016/j.ijpharm.2021.121067 ↗
2. Barbas · Cryst. Growth Des. · 2018 · 18 · 374010.1021/acs.cgd.8b00683 ↗
3. Butler · J. Pharm. Sci. · 2010 · 99 · 494010.1002/jps.22217 ↗
4. Chen · J. Am. Chem. Soc. · 2002 · 124 · 1501210.1021/ja017662o ↗
5. Coelho · J. Appl. Cryst. · 2018 · 51 · 21010.1107/S1600576718000183 ↗
6. Donnay · Am. Mineral. · 1937 · 22 · 446
7. Gemmi · ACS Cent. Sci. · 2019 · 5 · 131510.1021/acscentsci.9b00394 ↗
8. Gnutzmann · Cryst. Growth Des. · 2014 · 14 · 644510.1021/cg501287v ↗
9. Gruene · Angew. Chem. Int. Ed. · 2018 · 57 · 1631310.1002/anie.201811318 ↗
10. Guzmán · J. Pharm. Sci. · 2007 · 96 · 268610.1002/jps.20906 ↗
11. He · J. Pharm. Sci. · 2015 · 104 · 323710.1002/jps.24541 ↗
12. Hu · Mol. Pharm. · 2019 · 16 · 497810.1021/acs.molpharmaceut.9b00851 ↗
13. Jones · ACS Cent. Sci. · 2018 · 4 · 158710.1021/acscentsci.8b00760 ↗
14. Karothu · Angew. Chem. Int. Ed. · 2023 · 62 · e20230376110.1002/anie.202303761 ↗
15. Kistenmacher · J. Am. Chem. Soc. · 1972 · 94 · 134010.1021/ja00759a047 ↗
16. Kitaigorodskii · Acta Cryst. · 1965 · 18 · 58510.1107/S0365110X65001391 ↗
17. Klar · Nat. Chem. · 2023 · 15 · 84810.1038/s41557-023-01186-1 ↗
18. Klimakow · Langmuir · 2010 · 26 · 1123310.1021/la100540q ↗
19. Lightowler · Angew. Chem. Int. Ed. · 2024 · 63 · e20231769510.1002/anie.202317695 ↗
20. Lightowler · Angew. Chem. Int. Ed. · 2022 · 61 · e20211498510.1002/anie.202114985 ↗
21. Macrae · J. Appl. Cryst. · 2020 · 53 · 22610.1107/S1600576719014092 ↗
22. Newman, A. & Wenslow, R. (2016). AAPS Open 2:2.10.1186/s41120-016-0003-4 ↗
23. Palatinus · Acta Cryst. B · 2015 · 71 · 74010.1107/S2052520615017023 ↗
24. Peet · Ultramicroscopy · 2019 · 203 · 12510.1016/j.ultramic.2019.02.007 ↗
25. Pham · Mol. Pharm. · 2010 · 7 · 166710.1021/mp100205g ↗
26. Ricarte · Mol. Pharm. · 2019 · 16 · 408910.1021/acs.molpharmaceut.9b00601 ↗
27. Rigaku Oxford Diffraction (2020). CrysAlisPro. Rigaku Oxford Diffraction, Yarnton, UK.
28. S'ari · Mol. Pharm. · 2021 · 18 · 190510.1021/acs.molpharmaceut.0c00918 ↗
29. Schneider · Acta Cryst. D · 2002 · 58 · 177210.1107/S0907444902011678 ↗
30. Sundareswaran · Cryst. Res. Technol. · 2020 · 55 · 200008310.1002/crat.202000083 ↗
31. Surwase · Mol. Pharm. · 2013 · 10 · 447210.1021/mp400299a ↗
32. Van Duong · Mol. Pharm. · 2018 · 15 · 103710.1021/acs.molpharmaceut.7b00930 ↗
33. Vasconcelos · Drug Discovery Today · 2007 · 12 · 106810.1016/j.drudis.2007.09.005 ↗
34. Woollam · CrystEngComm · 2020 · 22 · 749010.1039/D0CE01216E ↗
35. Xie · J. Pharm. Sci. · 2017 · 106 · 10010.1016/j.xphs.2016.06.017 ↗